Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242097 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02242097 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 37 participants.
The verdict
NCT02242097, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy. This drug blocks an enzyme that affects how the lymphocytes grow and survive. The investigators hope to learn how safe and effective ibrutinib is for treating patients with MCL after responding to induction chemotherapy.
Interventions
- OTHER laboratory biomarker analysis
- DRUG ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-01-12 |
| Est. Completion | 2023-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02242097
The ClinicalTrials.gov registry entry for NCT02242097 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT02242097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02242097 about?
NCT02242097 is a clinical study titled "Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma". This study is being done to see whether or not a drug called ibrutinib can be given to patients with mantle cell lymphoma (MCL) as maintenance therapy after induction chemotherapy. This drug blocks an enzyme that affects how the lymphocytes grow and survive. The investigators hope to learn how safe ...
What is the current status of trial NCT02242097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2015-01-12. Estimated completion is 2023-01-05.
What interventions are being tested in trial NCT02242097?
The interventions under investigation include: laboratory biomarker analysis (OTHER), ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02242097?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.